First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis.

J Immunother · 2022 · PMC9528941 · PMID 36121316

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

borderline significanceP <0.1so close (0.05 < p ≤ 0.1)

Only the factors that showed statistical significance or borderline significance ( P <0.1) in the univariate analysis were added stepwise to the multivariate analysis.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.